TY - JOUR
T1 - Fractionated stereotactic radiotherapy for local control of resected brain metastases
AU - Traylor, Jeffrey I.
AU - Habib, Ahmed
AU - Patel, Rajan
AU - Muir, Matthew
AU - Gadot, Ron
AU - Briere, Tina
AU - Yeboa, Debra N.
AU - Li, Jing
AU - Rao, Ganesh
N1 - Publisher Copyright:
© 2019, Springer Science+Business Media, LLC, part of Springer Nature.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/9/1
Y1 - 2019/9/1
N2 - Purpose: Postoperative stereotactic radiosurgery (SRS) has been shown to establish local control in patients with resected brain metastases, yet its efficacy may be limited, particularly for resected lesions with large post-operative resection cavities. We describe the efficacy of postoperative fractionated stereotactic radiotherapy (FSRT) for local control in patients who have undergone resection for brain metastases. Methods: In this retrospective cohort study, we analyzed patients who received FSRT for resected brain metastases in 3 or 5 fractions. Time to local recurrence was the primary endpoint in this study. Results: Sixty-seven patients (n = 29 female, n = 38 male) met study criteria for review. The median age of the cohort was 62 years (range 18–79 years). Median preoperative tumor volume was 11.1 cm3 (range 0.4–77.0 cm3). The rate of local control was 91.0% at 6 months, 85.1% at 12 months, and 85.1% at 18 months. Estimates of freedom from local recurrence at 6 and 12 months were 90.9% and 84.3%, respectively. Higher biologically equivalent doses (BED10) were found to be predictive of longer freedom from local recurrence on univariate and multivariable analysis. Larger cavity volumes were found to correspond to longer time to local recurrence on univariate and multivariable analysis. Conclusion: Our results suggest that postoperative FSRT may be an effective method for providing local control to the surgical bed in patients with resected brain metastases, particularly for larger tumors not amenable to conventional, single-fraction SRS. Additional prospective studies are needed to confirm these findings.
AB - Purpose: Postoperative stereotactic radiosurgery (SRS) has been shown to establish local control in patients with resected brain metastases, yet its efficacy may be limited, particularly for resected lesions with large post-operative resection cavities. We describe the efficacy of postoperative fractionated stereotactic radiotherapy (FSRT) for local control in patients who have undergone resection for brain metastases. Methods: In this retrospective cohort study, we analyzed patients who received FSRT for resected brain metastases in 3 or 5 fractions. Time to local recurrence was the primary endpoint in this study. Results: Sixty-seven patients (n = 29 female, n = 38 male) met study criteria for review. The median age of the cohort was 62 years (range 18–79 years). Median preoperative tumor volume was 11.1 cm3 (range 0.4–77.0 cm3). The rate of local control was 91.0% at 6 months, 85.1% at 12 months, and 85.1% at 18 months. Estimates of freedom from local recurrence at 6 and 12 months were 90.9% and 84.3%, respectively. Higher biologically equivalent doses (BED10) were found to be predictive of longer freedom from local recurrence on univariate and multivariable analysis. Larger cavity volumes were found to correspond to longer time to local recurrence on univariate and multivariable analysis. Conclusion: Our results suggest that postoperative FSRT may be an effective method for providing local control to the surgical bed in patients with resected brain metastases, particularly for larger tumors not amenable to conventional, single-fraction SRS. Additional prospective studies are needed to confirm these findings.
KW - Brain metastases
KW - Fractionated stereotactic radiotherapy
KW - Postoperative
UR - http://www.scopus.com/inward/record.url?scp=85068962146&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068962146&partnerID=8YFLogxK
U2 - 10.1007/s11060-019-03233-9
DO - 10.1007/s11060-019-03233-9
M3 - Article
C2 - 31313060
AN - SCOPUS:85068962146
SN - 0167-594X
VL - 144
SP - 343
EP - 350
JO - Journal of neuro-oncology
JF - Journal of neuro-oncology
IS - 2
ER -